Progression-Free Survival Up to 1 Year [clinicaltrials_resource:18b8dc55c9cda30abf50514512270c1a]
Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Progression-Free Survival Up to 1 Year [clinicaltrials_resource:18b8dc55c9cda30abf50514512270c1a]
Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.
Bio2RDF identifier
18b8dc55c9cda30abf50514512270c1a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:18b8dc55c9cda30abf50514512270c1a
measure [clinicaltrials_vocabulary:measure]
Progression-Free Survival
time frame [clinicaltrials_vocabulary:time-frame]
Up to 1 Year
description
Median number of months before ...... re defined by RECIST criteria.
identifier
clinicaltrials_resource:18b8dc55c9cda30abf50514512270c1a
title
Progression-Free Survival Up to 1 Year
@en
type
label
Progression-Free Survival Up t ...... 8dc55c9cda30abf50514512270c1a]
@en